Kane receives clinical, preclinical data for revyve

Executive Summary

• Kane Biotech presented new clinical and preclinical data for its FDA-cleared revyve anti-microbial wound gel and spray at the Diabetic Foot Conference (DFCon 2025) and the Southern Region Burn Conference.
• Clinical data from Dr. Raymond Abdo and Dr. Peter Moyer showed revyve outperforming the standard of care for diabetic foot ulcers, achieving 97% average area reduction in four weeks and complete closure in 8-12 weeks.
• Preclinical data presented by Dr. Mack Drake demonstrated rapid anti-microbial efficacy in burn care, with a 99.99% to 99.9999% reduction in pathogens within 30 minutes and sustained anti-biofilm activity for seven days.

Key Details

• Diabetic Foot Ulcer Data (DFCon 2025):
  • Presented by Dr. Raymond Abdo (St. Louis Foot and Ankle Institute) and Dr. Peter Moyer (Foot & Ankle Institute of the Carolinas).
  • Achieved 97% average area reduction in four weeks, compared to the 40-50% benchmark for standard of care.
  • Achieved complete wound closure within eight to 12 weeks in all cases across a multicentre series.
  • Demonstrated sustained infection control and reduced bacterial bioburden throughout the healing process.
• Burn Wound Data (Southern Region Burn Conference):
  • Presented by Dr. Mack Drake (Burn and Reconstructive Centers of America).
  • Preclinical data showed a 99.99% to 99.9999% reduction in burn-associated pathogens within 30 minutes of application.
  • Sustained anti-biofilm activity was observed for seven days.
  • Represents up to a six-log reduction in microbial load within minutes.
• Strategic Context:
  • These results support the second pillar of Kane Biotech’s three-pillar strategy: reporting data at leading U.S. wound and burn care meetings.
  • Other pillars include conducting U.S.-based case series and rebuilding the U.S. distributor and sales agent network.
• Product Status:
  • revyve anti-microbial wound gel and spray are U.S. FDA 510(k) cleared.
  • revyve anti-microbial wound gel is Health Canada approved.

Notable Quotes

• "The usage of revyve gel has helped my patient proceed with increased healing wounds by keeping bacteria and bioburden at bay for hard-to-heal ulcerations," — Dr. Raymond Abdo
• "revyve is a great product for diabetic ulcers. It utilizes advanced skin healing technology to promote faster and more effective wound healing by managing biofilm. revyve has helped manage my diabetic patients with peripheral arterial disease, hemodialysis and elevated A1c," — Dr. Peter Moyer
• "revyve's ability to achieve up to a six-log reduction in microbial load within minutes while maintaining anti-biofilm protection for at least seven days represents a significant advancement in burn wound management -- reducing the frequency of dressing changes and helping ease the overall burden of care for patients," — Dr. Mack Drake
• "These findings underscore revyve's ability to improve upon the standard of care in both diabetic foot and burn management. revyve's anti-biofilm and anti-microbial technology continues to demonstrate its potential to transform wound healing outcomes," — Dr. Robert Huizinga, Interim CEO